Back to News
Market Impact: 0.42
Pharma stock soars 150% on injectables deal with Wegovy maker Novo
Source: CNBC
Healthcare & BiotechCompany Fundamentals
Swedish microcap drug-delivery company Nanexa's shares more than doubled after it disclosed a licensing agreement with European pharmaceutical major Novo Nordisk. The deal materially validates Nanexa's delivery technology and is likely to improve investor expectations for its commercial prospects.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.82
Ticker Sentiment
NANEXA0.90
NVO0.25
More News
- Yields keep rising, Novo's tough week, why cat product sales are surging and more in Morning Squawk
- Nanexa and Novo enter into EUR 1.165 billion global license and collaboration agreement for long-acting injectables
- Could This Be Novo Nordisk’s Next Billion-Dollar Weight-Loss Product?
- Stock Movers: UBS, Novo, Hello Fresh (Podcast)
- Shares of Akamai surge after deal with Anthropic. What Wall Street is saying
- Wall Street Week | China’s Trade Reckoning, Syracuse’s Second Chance, Humanoids in Healthcare